Phase 1/2 × INDUSTRY × Mesothelioma, Malignant × Clear all
NCT05086692 2025-07-09

ABILITY-1

Medicenna Therapeutics, Inc.

Phase 1/2 Recruiting
115 enrolled
NCT04104776 2025-05-15

A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

Novartis

Phase 1/2 Recruiting
275 enrolled
NCT05500508 2024-12-24

Oral AMXT 1501 Dicaprate in Combination With IV DFMO

Aminex Therapeutics, Inc.

Phase 1/2 Terminated
15 enrolled